Isabel Andia Ortiz

Currently, Isabel Andia Ortiz is the Group Head and Principal Investigator of the Regenerative Therapies group at IISS Biobizkaia, a position she has held since 2012 after transitioning from the Neurochemical Research Directorate within the Mental Health Network of OSAKIDETZA.

She holds a degree in Chemical Sciences from the University of the Basque Country (UPV/EHU) and specializes in Neurochemistry, having trained at the Neurochemical Research Directorate and Millhauser Laboratories at New York University. She earned her doctorate *cum laude* at UPV/EHU.

Dr. Andia specializes in platelet biology and platelet-rich therapies, a field she first explored during a research stay with Dr. AT Nurden and Dr. P. Nurden in Bordeaux. She collaborated with the Biotechnology Institute (BTI) and the "Mikel Sánchez" Arthroscopic Surgery Unit (UCA), advancing regenerative treatments such as platelet-rich plasma (PRP). From 2004 to 2010, she led tissue regeneration projects at BTI IMASD in Vitoria-Gasteiz.

Her current research focuses on Translational Medicine and Biomedical Innovation, with a particular emphasis on 3D bioprinting for clinical applications. She has published over 150 indexed articles and contributed to multiple book chapters. Dr. Andia is dedicated to leveraging these technologies to develop innovative solutions for chronic musculoskeletal disorders and complex wound healing challenges.

She also coordinates the "Innovation in Surgery, Biomedical Engineering, Bioinformatics, and Health Technologies" Research Area at the Biobizkaia Health Research Institute. Additionally, she is a member of the Scientific Council of the GRIIP, International Research Group on Platelet Injections.